Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 17, 2020Arthritis & RheumatologyOpen Access

Third‐Generation Anti–Cyclic Citrullinated Peptide Antibodies Improve Prediction of Clinical Arthritis in Individuals at Risk of Rheumatoid Arthritis

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAndrea Di MatteoUniversity of LeedsKMKulveer MankiaUniversity of LeedsLDLaurence DuquenneUniversity of Leeds

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Matteo et al. (2020) studied this question.

synapsesocial.com/papers/6a763c443025cdd732bcb31dhttps://doi.org/10.1002/art.41402
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide 2 antibody and anti-cyclic citrullinated peptide 3 antibody in rheumatoid arthritis2014 · 15 citations
  2. 2Performance of Anti–Cyclic Citrullinated Peptide Assays Differs in Subjects at Increased Risk of Rheumatoid Arthritis and Subjects With Established Disease2013 · 79 citations
  3. 3Value of anti–modified citrullinated vimentin and third‐generation anti–cyclic citrullinated peptide compared with second‐generation anti–cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis2009 · 166 citations
  4. 4Anti–citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis2009 · 256 citations